Publication | Closed Access

Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study

VaccinationVaccine DevelopmentVaccine TargetCo-formulated CocktailImmunologyAntibody EngineeringVaccine DesignImmunotherapyMedicineVaccine ResearchHuman Monoclonal AntibodiesEbola Virus Glycoprotein